RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective a4B2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders

Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective a4B2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders

Mazurov, A., Miao, L., Bhatti, B., Strachan, J., Akireddy, S., Murthy, S., Kombo, D., Xiao, Y., Hammond, P., Zhang, J., Hauser, T., Jordan, K., Miller, C., Speake, J., Gatto, G., & Yohannes, D. (2012). Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective a4B2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. Journal of Medicinal Chemistry, 55(22), 9793 - 9809.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Predictors of willingness to get a COVID-19 vaccine in the U.S
Article

Estimating regionalized planning costs of green infrastructure and low-impact development stormwater management practices
Article

Alpha-pyrrolidinopentiophenone and mephedrone self-administration produce differential neurochemical changes following short- or long-access conditions in rats
OCCASIONAL PAPER

Perceived, experienced, and internalized cancer stigma